Journal
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY
Volume 14, Issue 6, Pages 570-575Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ACI.0000000000000108
Keywords
asthma; IL-13; IL-4; monoclonal antibody
Categories
Funding
- NIH [F32DK091044]
- Genetech
- Novartis
- Boehringer Ingelheim
- GlaxoSmithKline
- Merck
- Pearl Pharmaceutical
Ask authors/readers for more resources
Purpose of reviewTo summarize recent advances in IL-4 and IL-13 blockade in the treatment of asthma.Recent findingsHistorically, anticytokine therapies have historically been unsuccessful in the treatment of asthma because of the heterogeneity of its pathogenesis. Recent advances in our understanding of asthma pathophysiology and our increased ability to phenotype patients have led to the identification of asthmatic subsets (endotypes) that are most likely to respond to anticytokine therapy. Several new biologic therapies targeting IL-13 or both IL-4 and IL-13 signaling are currently in clinical trials and both types of therapies have demonstrated therapeutic benefit.SummaryAnti-IL-4/13 therapies, guided by knowledge of an individual's underlying pathophysiology, are a promising class of therapies for treatment of asthma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available